Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...

The recent deal between Novo Nordisk and Hims & Hers is already resulting in new product announcements for Hims & Hers. The ...

Renowned health and wellness platform, Hims & Hers Health, Inc. HIMS is fundamentally built as a consumer-first digital ...

The crucial question is whether the terms of the partnership allow for profitable expansion or merely position HIMS as a ...

Hims & Hers stock traded more than 40% higher after the deal was announced.

These companies are benefiting from a tidal wave of demand for new weight-loss drugs.

The agreement brings an end to the legal dispute between the two companies. Hims & Hers shares jumped.

March 9 (Reuters) - Hims & Hers' shares were up over 40% on Monday, after Novo Nordisk agreed to sell its blockbuster Wegovy and Ozempic drugs through the telehealth firm's platform, signaling an end ...

Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see Novo Nordisk’s branded weight loss ...

Hims & Hers Health Inc. surged after Novo Nordisk A/S was said to have ended its public feud with the company with an agreement to sell its weight-loss drugs on the Hims platform.

HIMS stock soars on a settlement and partnership with Novo Nordisk. But Hims & Hers shares are unlikely to sustain these ...

Telehealth company Hims & Hers on Monday announced a “strategic shift” in its business model, partnering with pharmaceutical company Novo Nordisk to sell its blockbuster GLP-1 medication and stop ...